Medindia
Medindia LOGIN REGISTER
Advertisement

Neurocrine Biosciences Presents New KINECT�-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA� (valbenazine) Capsules

Monday, March 17, 2025 Drug News
Advertisement
PR Newswire

SAN DIEGO, March 17, 2025

SAN DIEGO, March 17, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the KINECT�-HD study showcasing significant improvements in chorea across body regions with once-daily INGREZZA� (valbenazine) capsules in adults with Huntington's disease. The post-hoc analysis was presented at the Neuroscience Advanced Practice Provider�Symposium hosted by the American Association of Neuroscience Nurses in New Orleans.
Advertisement



"This analysis reinforces the primary study findings, showing the consistent benefit of INGREZZA in reducing the involuntary movements of chorea that can affect any part of the body," said Eiry W. Roberts, M.D., Chief Medical Officer, Neurocrine Biosciences. "Notably, the most significant improvements were seen in the arms and legs, which were the most severely affected at baseline. These results are meaningful because they show how INGREZZA alleviates chorea symptoms and therefore helps people with Huntington's disease in their everyday lives."
Advertisement

In the 12-week, Phase 3 KINECT-HD clinical trial, once-daily INGREZZA demonstrated a significant reduction in chorea severity, as measured by the Unified Huntington's Disease Rating Scale (UHDRS�) Total Maximal Chorea (TMC) score, which measures chorea in seven body regions (face, buccal-oral-lingual region, trunk, right and left upper extremities, right and left lower extremities). This post-hoc analysis was conducted to assess the effect of INGREZZA on chorea by individual body region.

In the KINECT-HD study, patients were randomized 1:1 to receive INGREZZA (n=64) at doses of 40 mg, 60 mg or 80 mg, or placebo (n=61).�TMC scores at baseline were similar between treatment groups. Key findings from the post-hoc analysis include:

About Chorea Associated with Huntington's Disease�Huntington's disease (HD) is a hereditary progressive neurodegenerative disorder in which the loss of certain neurons within the brain causes motor, cognitive and psychiatric symptoms. Symptoms generally appear between the ages of 30 and 50 years and worsen over a 10- to 25-year period. Most people with HD experience chorea, an abnormal involuntary movement disorder, characterized by irregular and unpredictable movements. Chorea can affect various body parts and interfere with motor coordination, gait, swallowing and speech. HD is estimated to affect approximately 41,000 adults in the�U.S., with more than 200,000 at risk of inheriting the disease.

About KINECT�-HDKINECT�-HD was a Phase 3, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of valbenazine as a once-daily treatment to reduce chorea associated with�Huntington's disease (HD) and evaluate the safety and tolerability of valbenazine in patients with HD. The study enrolled 128 adults 18 to 75 years of age who were diagnosed with motor-manifest HD and who had sufficient chorea symptoms to meet study protocol criteria.

KINECT-HD used the Unified Huntington's Disease Rating Scale (UHDRS�) Total Maximal Chorea (TMC) score as the primary efficacy endpoint. The secondary endpoints included Clinical Global Impression of Change (CGI-C) response status and Patient Global Impression of Change (PGI-C) response status for valbenazine treatment. Treatment with valbenazine resulted in a placebo-adjusted mean reduction in the TMC score of 3.2 units (P<0.0001), indicating a substantial improvement in chorea. Secondary endpoints of CGI-C response status and PGI-C response status were also statistically significant and supported the improvements in TMC score that were seen over the 12-week study period.

Treatment-emergent adverse events in this study were generally consistent with the known safety profile of valbenazine. The most common adverse reactions in patients with HD included somnolence and sedation, urticaria, rash and insomnia.

View the complete study results from the Phase 3 KINECT-HD study published in�The Lancet Neurology�online edition. For more information on the KINECT-HD study, please visit HuntingtonStudyGroup.org.

About INGREZZA��(valbenazine) Capsules and INGREZZA��SPRINKLE (valbenazine) CapsulesINGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the�U.S. Food and Drug Administration�for the treatment of adults with tardive dyskinesia and the treatment of chorea associated with Huntington's disease (HD). Only INGREZZA offers a therapeutic dose from day one with no required titration.

INGREZZA, developed by�Neurocrine Biosciences, selectively inhibits VMAT2 with no appreciable binding affinity for VMAT1, dopaminergic (including D2), serotonergic, adrenergic, histaminergic or muscarinic receptors. While the specific way INGREZZA works to treat TD and HD chorea is not fully understood, INGREZZA is unique in that it selectively and specifically targets VMAT2 to inhibit the release of dopamine, a chemical in the brain that helps control movement. INGREZZA is believed to reduce extra dopamine signaling, which may lead to fewer uncontrollable movements.

INGREZZA is proven across the widest range of patients. It is always one capsule, once daily and can be taken together with most stable mental health regimens such as antipsychotics or antidepressants. Only INGREZZA offers the benefit of a sprinkle formulation, INGREZZA��SPRINKLE, for those who experience dysphagia, have difficulty swallowing or prefer not to swallow a pill. INGREZZA and INGREZZA SPRINKLE dosages approved for use are 40 mg, 60 mg and 80 mg capsules.�

Important Information

Approved UsesINGREZZA��(valbenazine) capsules or INGREZZA��SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with:

It is not known if INGREZZA or INGREZZA SPRINKLE is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INGREZZA or INGREZZA SPRINKLE can cause serious side effects in people with Huntington's disease, including: depression, suicidal thoughts, or suicidal actions.�Tell your healthcare provider before you start taking INGREZZA or INGREZZA SPRINKLE if you have Huntington's disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA or INGREZZA SPRINKLE is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.

Do not take INGREZZA or INGREZZA SPRINKLE if you:

INGREZZA or INGREZZA SPRINKLE can cause serious side effects, including:

Before taking INGREZZA or INGREZZA SPRINKLE, tell your healthcare provider about all of your medical conditions including if you:�have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.�

Tell your healthcare provider about all the medicines you take,�including prescription and over-the-counter medicines, vitamins, and herbal supplements. Make sure you tell all of your healthcare providers that you are taking INGREZZA or INGREZZA SPRINKLE. Taking INGREZZA or INGREZZA SPRINKLE with certain other medicines may cause serious side effects. Especially tell your healthcare provider if you: take digoxin or take or have taken a monoamine oxidase inhibitor (MAOI) medicine. You should not take INGREZZA or INGREZZA SPRINKLE if you are taking, or have stopped taking, a MAOI within the last 14 days.

The most common side effect of INGREZZA or INGREZZA SPRINKLE in people with tardive dyskinesia�are�sleepiness and tiredness.

The most common side effects of INGREZZA or INGREZZA SPRINKLE in people with chorea associated with Huntington's disease include�sleepiness and tiredness, raised itchy red areas on your skin (hives), rash, and trouble getting to sleep or staying asleep.

These are not all of the possible side effects of INGREZZA or INGREZZA SPRINKLE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at�www.fda.gov/medwatch�or call�1-800-FDA-1088.

Dosage Forms and Strengths:�INGREZZA and INGREZZA SPRINKLE are available in�40 mg, 60 mg, and 80 mg capsules.

Please see full�Prescribing Information, including Boxed Warning, and Medication Guide.

About�Neurocrine Biosciences, Inc.Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit�LinkedIn,�X and�Facebook. (*in collaboration with AbbVie)�

The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, KINECT�and INGREZZA are registered trademarks of�Neurocrine Biosciences, Inc.

Forward-Looking StatementsIn addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from INGREZZA for the treatment of chorea associated with Huntington's disease (HD) and the value INGREZZA may bring to patients with chorea associated with HD. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties associated with�Neurocrine Biosciences'�business and finances in general, as well as risks and uncertainties associated with the commercialization of INGREZZA for the treatment of chorea associated with HD; whether INGREZZA receives adequate reimbursement from third-party payors; the degree and pace of market uptake of INGREZZA for the treatment of chorea associated with HD; risks and uncertainties relating to competitive products and technological changes that may limit demand for INGREZZA for the treatment of chorea associated with HD; risks associated with the Company's dependence on third parties for development and manufacturing activities related to INGREZZA for the treatment of chorea associated with HD, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for INGREZZA for the treatment of chorea associated with HD or other product candidates may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding INGREZZA for the treatment of chorea associated with HD; risks that post-approval INGREZZA commitments or requirements may be delayed; risks that INGREZZA for the treatment of chorea associated with HD may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Company's periodic reports filed with the�Securities and Exchange Commission, including without limitation the Company's annual report on Form 10-K for the year ended December 31, 2024.�Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.

� 2025�Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US- 0049�� 03/2025

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-presents-new-kinect-hd-data-showing-significant-reduction-in-chorea-across-body-regions-with-ingrezza-valbenazine-capsules-302402275.html

SOURCE Neurocrine Biosciences, Inc.
Sponsored Post and Backlink Submission


Latest Press Release on Drug News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close